CELZ (Creative Medical Technology Holdings) Research & Development: $2.06 Mil (TTM As of Mar. 2026)


CELZ Creative Medical Technology Holdings Inc CELZ
36 GF Score
Price $2.06
GF Value $0.32
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Creative Medical Technology Holdings Research & Development?

Creative Medical Technology Holdings CELZ +2.97% 36 Research & Development is $2.06 Mil as of Mar. 2026. GuruFocus rates CELZ with a GF Score™ of 36/100 and a GF Value™ of $0.32 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Creative Medical Technology Holdings's Research & Development for the three months ended in Mar. 2026 was $0.54 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $2.06 Mil.

Creative Medical Technology Holdings  (NAS:CELZ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Creative Medical Technology Holdings Research & Development Related Terms

Creative Medical Technology Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Creative Medical Technology Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Creative Medical Technology Holdings Research & Development Chart

Creative Medical Technology Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 6.27 1.97 2.40 2.26

Creative Medical Technology Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.50 0.47 0.55 0.54
CELZ
36GF Score
Creative Medical Technology Holdings Inc CELZ
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Creative Medical Technology Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $2.06 Mil mean?
Creative Medical Technology Holdings (CELZ) has a Research & Development of $2.06 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Creative Medical Technology Holdings and its competitors.
Is Creative Medical Technology Holdings' Research & Development too high?
Creative Medical Technology Holdings' current Research & Development is $2.06 Mil. Overall, Creative Medical Technology Holdings has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' Research & Development compare to APM and BCLI?
Creative Medical Technology Holdings' Research & Development of $2.06 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Creative Medical Technology Holdings and its competitors. Creative Medical Technology Holdings's current Research & Development is $2.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $2.06 — trading 543.6% above its estimated fair value. The current Research & Development is $2.06 Mil. Creative Medical Technology Holdings' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current Research & Development is $2.06 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?

Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued. The current stock price of $2.06 is trading 543.6% above its estimated GF Value™ of $0.32. GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.

Key valuation signals for CELZ:

  • Research & Development: $2.06 Mil
  • GF Value™: $0.32 vs. price of $2.06 (543.6% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Creative Medical Technology Holdings Business Description

Address 211 E Osborn Road, Phoenix, AZ, USA, 85012
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
36GF Score

Get the complete analysis for CELZ

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.06
Price
$0.32
GF Value